they are aiming to finish cohort 4 by end of calendar year, but that is contingent on the other two trial sites opening up.
but cohort 3 will be this year, SNO (cohort 1 was presented there in Nov21- largest neurology conference in the US) in Nov would be an ideal time for cohort 4 or at minimum cohort 3 with follow up. and imo if they see something beyond disease control… they may not wait for the whole cohort to be dosed to release something.
CLTX-CAR T is a game changer, page-81
Add CHM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.76M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $9.531K | 515.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 1853294 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
| CHM (ASX) Chart |